Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2021-12-09
Product name
TRIUMEQ TABLETS
Product Synonyms
TRELAVUE * DOLUTEGRAVIR, ABACAVIR, LAMIVUDINE FIXED DOSE COMBINATION
Icons in SDS
Company Information
company name
GlaxoSmithKline US
e-mail address of the competent person responsible for the Safety Data Sheet
msds@gsk.com
GHS Information
Signal word
Danger
Section 2
Physical hazards
Not classified.
Health hazards
Germ cell mutagenicity Category 2 Carcinogenicity Category 1B Reproductive toxicity Category 2 Specific target organ toxicity, repeated Category 2 exposure
Environmental hazards
Hazardous to the aquatic environment, acute Category 2 Hazardous to the aquatic environment, Category 2
Long term hazards
OSHA defined hazards Not classified.
Signal word
Danger
Hazard statements
Suspected of causing genetic defects. May cause cancer. Suspected of damaging fertility or the unborn child. May cause damage to organs through prolonged or repeated exposure. Toxic to aquatic life. Toxic to aquatic life with long lasting effects.
Prevention
Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapors/spray. Avoid release to the environment. Wear protective gloves/protective clothing/eye protection/face protection.
Response
If exposed or concerned: Get medical advice/attention. Collect spillage.
Storage
Store locked up.
Disposal
Not available. Hazard(s) not otherwise Caution - Pharmaceutical agent. See section 11 of the SDS for additional information on health
Classified (HNOC)
hazards.
Additional information
21% of the mixture consists of component(s) of unknown acute oral toxicity. 92% of the mixture consists of component(s) of unknown acute dermal toxicity. 46% of the mixture consists of component(s) of unknown acute hazards to the aquatic environment. 28% of the mixture consists of component(s) of unknown long-term hazards to the aquatic environment.
